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A novel complex, [Cu(acetylethTSC)Cl]Cl•0.25C2H5OH 1 (where acetylethTSC = (E)-N-ethyl-2[1-(thiazol-2-yl)ethylidene]hydrazinecarbothioamide), was shown to have anti-proliferative
activity against various colon and aggressive breast cancer cell lines. In vitro studies showed that
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complex 1 acted as a poison inhibitor of human topoisomerase IIα, which may account for the
observed anti-cancer effects.

Graphical abstract
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The limited efficacy of current treatments for advanced breast and colon cancers has served
as an impetus for a concerted effort to identify chemo-preventive agents for treatment. This
process has often involved the use of metal complexes.[1] Cisplatin is widely used for the
treatment of many cancers[2] despite its high toxicity, undesirable side effects, and problems
with drug resistance in primary and metastatic cancers.[3] These limitations have spurred a
growing interest in novel non-platinum metal complexes that can show anti-cancer
properties.[4] Ruthenium-containing complexes have been reported to possess several
favourable properties suited to rational anti-cancer drug design,[5] and ruthenium-containing
complexes of various types are actively studied as metallodrugs, as they are believed to have
low toxicity and good selectivity for tumours.[6] Recently, we reported the effect of
ruthenium(II) complexes with new chelating thiosemicarbazones on growth inhibition of
MCF-7 and MDA-MB-231 (breast adenocarcinoma) as well as HCT 116 and HT-29
(colorectal carcinoma) cell lines.[7] Thiosemicarbazones and their metal complexes are used
in many applications, ranging from pharmacology to nuclear medicine.[8] We have
expanded our efforts by searching for non-ruthenium systems, for example; the use of
gallium(III)- and vanadium(IV)-containing complexes with thiosemicarbazones as ligands,
as potential anti-cancer agents.[9, 10] Copper(II) thiosemicarbazone complexes in particular
have been the focus of investigation as metallodrugs for various medical applications for a
long period of time. These applications include use as anti-cancer agents.[11, 12]
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A number of copper(II) complexes have been shown to have anti-tumour activity, and their
mechanism of action is believed to be inhibition of human topoisomerase IIα.[13, 14]
Topoisomerases are attractive targets for anti-cancer drugs. They are ubiquitous enzymes
that are required for untangling DNA and restoring the native DNA topology after processes
such as replication, transcription, and other events that distort the DNA topology.[15]
Topoisomerases are essential for cell viability. These enzymes employ an active site tyrosine
residue to attack the phosphodiester backbone of the DNA, causing the strand to break. The
enzyme then passes the other strand through the break, religates it, and releases the now
untangled DNA.[15, 16] An important feature of this mechanism is the ensuing covalent
intermediate where the enzyme is covalently linked to the cleaved DNA. While this
intermediate persists, the cell is in danger, as accumulation of DNA breaks can cause DNA
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damage response in cells, and even apoptosis.[16] Topoisomerase poison inhibitors that can
stabilize this covalent intermediate can be extremely effective anti-bacterial or anti-cancer
drugs.[17]
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Human topoisomerase IIα (hTop2α) is highly expressed in many cancer cells, which makes
it an attractive target for anti-cancer drugs.[18] There have been many reports of metalbased complexes inhibiting human topoisomerase IIα, including some platinum complexes
and other copper complexes as well, as mentioned above.[13, 14, 19, 20] However, many of
these previous findings with copper(II) complexes have not shown poison inhibition of
hTop2α, but rather catalytic inhibition, or have not determined the mechanism of
topoisomerase inhibition at all. The identification of a novel poison inhibitor is significant,
because topoisomerase poisons are highly effective anti-cancer agents. Poison inhibitors are
highly effective because trapping of the covalent intermediates formed by only a small
percentage of the target topoisomerases on cleaved chromosomal DNA by the drugs is
sufficient to initiate cancer cell death. In contrast, near complete inhibition of the catalytic
activity of the target enzyme may be needed for a catalytic inhibitor of an essential enzyme
to be effective in cancer cell growth inhibition.[21]
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Here, our research efforts have been extended to a novel copper(II) complex, which bears
the thiosemicarbazone, E)-N-ethyl-2-[1-(thiazol-2yl)ethylidene]hydrazinecarbothioamide[10] (acetylethTSC). As such, we now report the
characterization of a novel copper(II) complex, complex 1, which can act as an anti-tumour
agent and as an hTop2α poison inhibitor. To our knowledge, this complex is the first
copper(II)-based complex to show measurable quantitative increases in the linear DNA
cleavage product from trapped topoisomerase complex, with specificity to hTop2α over the
hTop1. The poisoning of hTop2α is likely to lead to cell death, and may contribute
significantly to the anti-cancer mode of action.
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Complex 1 was prepared by reacting the thiosemicarbazone, (E)-N-ethyl-2-[1-(thiazol-2yl)ethylidene]hydrazinecarbothioamide (acetylethTSC) in ethanol (Scheme 1). The complex
was characterised by elemental analysis, HRMS, FTIR, UV-visible, and ESR
spectroscopies. ICP-MS was also used to determine the percentage of Cu in the sample. The
elemental analysis data for the percentage of H is not fully consistent with the calculated
value; this could be due to the fact that the discrepancy is only in the percentage of H, and is
more likely due to an error in the analysis process. Based on this discrepancy, it was
necessary to show the HRMS data which showed an m/z value of 614.912544 (Figure S1) of
which the proposed binuclear complex 2 was detected from a methanolic solution. In
complex 2 (as a binuclear species), the acetylEtTSC ligand was found to coordinate as a
thiolate anion while being detected in the positive mode while in the chamber of the mass
spectrometer. This is due to the fact that thiosemicarbazones ligands can exist as thione–
thiol tautomers (although the proton lost to form the anion formally belongs to the
hydrazinic -NH group).[11] Such thiosemicarbazones can undergo tautomerisation and
subsequent deprotonation of the thiol form allowing for a mono-anionic ligand.[11]
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Chemical Formula: C16 H22 CICu 2 N8 S4
Exact Mass: 614.91
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The complex was soluble in DMSO as revealed by its UV-visible spectrum in DMSO
(Figure S2, ESI). It is really clear that there are differences between the UV-visible spectra
of the ligand and the complex (Figure S2, ESI). The UV-visible spectrum of complex 1
shows a d–d transition, which has a molar extinction coefficient value of 182 M−1 cm−1 at
624 nm. Complex 1 also showed other bands at 324 and 425, with molar extinction values of
1.7 × 104 and 1.6 × 104 M−1 cm−1, respectively. In DMSO, the “free” ligand has a
wavelength of 340 nm, with a molar extinction coefficient value of 2.8 × 104 M−1 cm−1.
Conductivity measurements of a 1.0 mM DMSO solution of complex 1, where Λm = 31.0 ±
2.0 μS cm−1 proved the existence of complex 1 as a 1:1 electrolyte based on the use of
conductivity measurements to ascertain types of electrolytes in various solvents as reported
in a review as written by Geary.[22] Complex 1 as a 1:1 electrolyte accounts for the
presence of a mononuclear cation in DMSO.
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The infrared spectrum of complex 1 (Figure S3, ESI) shows a band in the ν(N-H) region
which may be attributed to the hydrazinic nitrogen, thus suggesting that the ligands are
coordinated as the thione form.[10] The ligand is reported to have stretching frequencies of
3164, 3054, and 1059, as designated for ν(-N1H), ν(N2H), and ν(N2-N3), respectively.[10]
On the other hand, complex 1 exhibited stretching frequencies of 3190, 2973, and 1166, as
designated for ν(-N1H), ν(N2H), and ν(N2-N3), respectively. The presence of a medium
stretching frequency for C=S at 813 cm−1 was determined for the “free” ligand,[10] but
upon coordination, this stretching frequency is decreased to 787 cm−1 for the presence of
C=S in the thione form of the coordinated thiosemicarbazone.[10] Also, the strong
stretching frequency assigned to the ν(C=N) in the spectrum occurs at 1543 cm−1,[10] but is
shifted to 1567 cm−1, thus implying that there is coordination of the azomethine (C=N) to
the copper(II) metal centre.[23] The stretching frequency at 1296 (ν(C=S) + ν (C=N)) is
shifted to 1228 cm−1 in the FTIR spectrum for complex 1.
The ESR spectra in a frozen solution of DMSO shows the presence of a paramagnetic Cu(II)
metal centre, where g⏊, g∥, A⏊, and A∥ were determined to be 2.0525, 2.1888, 12 G, and
168.9 G, respectively (Figure S4, ESI). The ESR spectrum of the complex indicates an axial
Inorg Chem Commun. Author manuscript; available in PMC 2017 February 01.
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symmetry. As g∥ > g⏊ > 2.002, it can be inferred that the complex possesses an
approximately square-planar geometry. This trend is also consistent with a dx2−y2 ground
state.[24, 25] Sakaguchi and Addison[25] have shown that the g∥/A∥ ratio can be used as a
convenient empirical index of tetrahedral distortion in CuN4 units. This value ranges from
ca. 105 to 135 cm for the square planar structure, and this quotient increases on the
introduction of tetrahedral distortion to the chromophore. Furthermore, tetrahedral distortion
of a square-planar chromophore is observed when any (N, O, S) donors reduce A∥ and
increase g∥. Using that relationship and the g∥/A∥ ratio of 139 cm (where g∥/A∥ =
(2.1888/0.01579) cm) results in complex 1 having a tetrahedral distortion from the square
planar geometry, and this is reflected in the structure for complex 1 as shown in Scheme 1.
Such is structure is also based on the fact that the ligand can be tridentate in nature.
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Electrochemical studies were also carried out on the ligand and complex 1, where some
interesting features were observed in each cyclic voltammogram (Figure S5, ESI) for the
metal centre and the thiosemicarbazone ligand (both coordinated and “free”). Recently,
electrochemical studies of thiosemicarbazones has shown the existence of an irreversible
cathodic redox peak in the region −1.26 V to −1.67 V, corresponding to the reduction of the
imine moiety of the thiosemicarbazone functional group.[26] Such a case was observed of
the “free” ligand, where Epc = −1.62 V is believed to be due to the reduction of the imine
moiety. The redox potential, Epa = +0.704 V, is believed to be arise from the oxidation of
the “free” ligand to a highly reactive radical cation followed by the formation of a dimeric
species containing a disulphide bond.[27] The reduction of the thione functional group of a
thiosemicarbazone moiety, have previously been reported to produce an irreversible
cathodic peak at −1.06 V.[28] Previously reported electrochemical studies on
thiosemicarbazone ligands have also shown the existence of an irreversible cathodic peak at
−1.06 V.[28] We believe that the redox couple of E½ = −0.668 V is due to the reduction of
the thione functional group. The cyclic voltammogram for complex 1 shows redox couples
that are ligand- and metal-based. The irreversible Epa = +0.539 V is believed to be arise
from the oxidation of the coordinated ligand to a highly reactive radical cation; while the
irreversible Epc = −1.52 V is believed to be due to the reduction of the imine moiety. On the
other hand the redox couple (CuII/I) is reversible at E½ = −0.207 V.
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Once characterized, the anti-proliferative activity of complex 1 was carried out against colon
cancer cell lines (HTC-116, Caco-2, and HT-29), and also compared to the anti-proliferative
activity against one non-cancerous colon cell line (CCD-18Co). Complex 1 and etoposide
(as positive control) were evaluated for their cytotoxicity against HCT-116, Caco-2, and
HT-29 by a colorimetric assay (MTS), as described by Lewis et al.[10] Table S1 (ESI)
summarizes the data from this evaluation. The effects of the compounds on the viability of
these cells were evaluated after continuous incubation (24, 48, and 72 hours). In all cases, it
was found that complex 1 had better efficacy in inhibiting cell growth of the colorectal
cancer cells when compared to etoposide as shown in Table S1. Complex 1, however, was
found to be very toxic to the non-cancerous colon cell line (CCD-18Co) when compared to
etoposide, with IC50 values after 72 hours of 0.83 ± 0.80 and 41.2 ± 2.3 μM, respectively.
Based on the results from the above study, where it was found that complex 1 was very
aggressive in inhibiting cell growth of these colorectal cancer cell lines, we decided to carry
Inorg Chem Commun. Author manuscript; available in PMC 2017 February 01.
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out an in vitro study on very aggressive breast cancer lines that are highly malignant and
demonstrate increased rates of cell growth, migration and invasion. As such, to extend the
potential anti-oncogenic of complex 1, we examined its ability to prevent breast cancer cell
proliferation in a preliminary study. In this preliminary study, we demonstrated a significant
decrease in cell proliferation in four (4) different aggressive breast cancer cell lines, viz.,
HCC 1500, HCC 70, HCC 1806, and HCC 1395. The results (Figures S6–S9, ESI) that were
obtained when HCC1500 cells were treated with the complex 1 at the concentrations
indicated in each figure (Figures S6–S9, ESI) before incubation for 24 and 48 hours. The
rate of cell proliferation was determined using an MTT cell proliferation assay. Each value
is presented as the mean of the SEM of three independent determinations. The columns in
each graph are presented as relative values in comparison to serum-starved cells. Bars
labelled with different letters are significantly different from one another (P < 0.05). The
black horizontal line denotes the level at which the rate of cell proliferation has been
decreased by 50% of the growth factor control (positive control, yellow bar). The results
(Figures S6–S9, ESI) demonstrated that complex 1 is able to prevent growth factorstimulated cell proliferation at concentrations ranging from 1 μM to 20 μM in all the cell
lines assayed. Complex 1 was tested for its ability to prevent cell growth after being exposed
to the cells for 24 and 48 hours, respectively. The exposure to complex 1 for 48 hours did
not result in dramatic decreases in cell growth, suggesting that a 24 hour exposure to this
complex was significant enough to prevent breast cancer cell proliferation.
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Specifically, 5 μM of complex 1 was sufficient to reduce cell proliferation by 50% in all the
cell lines after 24 hours (note black horizontal line on each figure (Figures S6–S9, ESI)).
Additionally, with a longer exposure to the complex (48 hours), the amount of complex 1
needed to reduce 50% of cell proliferation was only 2 μM for the HCC 70, HCC 1500, and
HCC 1806 cell lines, however it remained at 5 μM for the HCC 1395 cell lines. This is
interesting, since the HCC 1395 cell line is the only cell line that is derived from a
Caucasian-American female, while the other three cell lines are derived from AfricanAmerican females.
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To understand the complex’s mechanism for exerting toxicity on the cancer cell lines, the
effect of the complex on hTOP2α activity was evaluated, since many anticancer drugs are
known to target this enzyme. The complex’s effects on htop2α were determined in vitro. A
standard assay for detecting topoisomerase inhibition involves gel electrophoresis; the
enzyme’s ability to relax supercoiled DNA is determined in the presence and absence of the
compound of interest.[29] When complex 1 was incubated with hTop2α, it prevented the
enzyme’s ability to relax DNA. It was shown to inhibit the relaxation activity of human
topoisomerase IIα with an IC50 value of 12.5–25 μM (Figure 1). The ligand alone has no
effect on the enzyme activity.
Complex 1, in addition to inhibiting the relaxation activity of hTop2α, also produced an
increase in the linear DNA cleavage product. The presence of linear DNA product indicates
that the complex can act as a poison inhibitor of human topoisomerase IIα. As mentioned
earlier, poison inhibitors prevent DNA religation following cleavage by the topoisomerase
enzyme. The DNA-enzyme covalent intermediate persists, and the DNA is trapped with a
double stranded break.[17] Figure 2 shows the increase in cleavage product observed for
Inorg Chem Commun. Author manuscript; available in PMC 2017 February 01.
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complex 1. Free copper in the form of the copper(II) salt, CuCl2•2H2O, did not result in any
significant increase in topoisomerase cleavage product. Densitometry analysis of the bands
shows a 3.6-fold increase in linear DNA product when compared to the DMSO lane
(negative control) for complex 1 at 100 μM, and a 2.8-fold increase at 25 μM.
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These results are significant, because a quantitative increase in linear DNA cleavage product
was not observed for other copper(II)-containing complexes reported in previous studies, for
example, 1-((5(or 6)-carboxy-1H-benzo[d]imidazol-2-yl)methyl)pyridinium copper(II)
chloride hydrate,[13] copper(II) complexes with α-heterocyclic thiosemicarbazones as
ligands,[14] and an R- and S-enantiomeric copper(II) complex derived from N,N-bis(1benzyl-2-ethoxyethane),[19] all of which showed either little or no poisoning effect. In our
study, this novel effect is significant, since the accumulation of topoisomerase cleavage
intermediates would be an important mode of action for anti-cancer activity. Additionally,
“free” Cu(II) ions and the acetylethTSC ligand were not able to poison the topoisomerase on
their own, but it is the complex that is formed from the copper(II) metal centre and the
ligand that exerted the poisoning effect.
To determine specificity, complex 1 was tested against human topoisomerase I. It exhibited
little to no effect on the enzyme relaxation activity, supporting the hypothesis that complex 1
can act as a specific inhibitor of hTop2α. Its effect on the type I enzyme is shown in Figure
3.
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This copper(II) complex is the first of its kind to show measurable quantitative increases in
the linear DNA cleavage product from hTop2α. The quantitative increase in linear DNA (as
shown in Figure 2 is indicative of a poison mechanism of inhibition, as an hTop2α poison
would cause an increase in permanent double-stranded breaks. This mechanism of action is
particularly lethal, and may account for the anti-proliferative effects exerted on the various
cancer cell lines studied in this work reported within. Only a few stabilized htop2α covalent
complex trapped by complex 1 on chromosomal DNA may be sufficient to initiate the
apoptosis pathway. At 12.5 μM complex 1, the linear DNA product formed by htop2α on
plasmid DNA increased by 30% as determined by densitometry analysis. Cytotoxicity from
complex 1 could be observed at submicromolar concentrations. The level of htop2α covalent
complex that can be trapped by complex 1 on chromosomal DNA in tumour cells might be
further enhanced by the involvement of htop2α in DNA replication complexes. It is also
possible that there may be additional mode of actions involved in the anti-tumour activity of
complex 1. The in vivo effect of complex 1 and similar copper complexes should be
investigated further in future studies.
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Highlights (for review)
•

A novel copper(II) complex with (E)-N-ethyl-2-[1-(thiazol-2yl)ethylidene]hydrazinecarbothioamide) was synthesized and characterized

•

Anti-proliferative activity against various colon (in one case, an IC50 value of
242 nM) and aggressive breast cancer cell lines

•

In vitro studies showed that compound acted as a poison inhibitor of human
topoisomerase IIα, which is unlike most copper(II) complexes
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The effect of inhibition of hTop2α relaxation activity by complex 1. Lane 1: negatively
supercoiled pBAD/Thio plasmid DNA with no enzyme; Lane 2: DMSO as negative control;
Lane 3: positive control mAMSA at 75 μM; Lanes 4–6: 100, 50, and 25 μM acetylethTSC;
Lanes 7–10: 100, 50, 25, and 12.5 μM complex 1. N = nicked, FR= fully relaxed, PR =
partially relaxed, and S = supercoiled.
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The effect of poisoning of hTop2α in the presence of complex 1. Lane 1: negatively
supercoiled pBAD/Thio plasmid DNA with no enzyme; Lane 2: DMSO as negative control;
Lane 3: positive control mAMSA at 25 μM; Lanes 4–6: 200, 100, and 50 μM CuCl2•2H2O;
Lanes 7–9: 100, 50, and 25 μM acetylethTSC; Lanes 10–13: 100, 50, 25, and 12.5 μM
complex 1. Electrophoresis buffer contained 0.5 μg ml−1 ethidium bromide. N = nicked, L =
linear, and CC = covalently closed.
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The effect complex 1 on human topoisomerase I activity. Lane 1: negatively supercoiled
pBAD/Thio plasmid DNA; Lane 2: DMSO as negative control; Lane 3: positive control
camptothecin at 100 μM; Lanes 4–6: 100, 50, and 25 μM acetylethTSC; Lanes 7–10: 100,
50, 25, and 12.5 μM complex 1. N = nicked, FR = fully relaxed, PR = partially relaxed, and
S = supercoiled.
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Scheme 1.

Synthesis of complex 1.
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